Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, May 23, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding UnitedHealth Group Inc. (NYSE: UNH), Endo International PLC (NASDAQ: ENDP), Baxter International Inc. (NYSE: BAX), Edwards Lifesciences Corp (NYSE: EW) and Aetna Inc (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2837-100free.
--
UnitedHealth Group Inc. Analyst Notes
On May 16, 2014, UnitedHealth Group Inc. (UnitedHealth Group) reported that the Company along with its benefits and services businesses, UnitedHealthcare and Optum, are working to support the victims of wildfires in San Diego County. According to the Company, the supportive work includes arrangement of a free emotional-support line by Optum to help people in the affected communities as well as assisting health plan participants in the UnitedHealthcare network, who may be affected and need to make arrangements to ensure continuity of care. The full analyst notes on UnitedHealth Group are available to download free of charge at:
http://www.analystsreview.com/2837-UNH-23May2014.pdf
--
Endo International PLC Analyst Notes
On May 19, 2014, Endo International PLC (Endo) announced that its affiliates have completed the acquisition of the worldwide rights to Sumavel®DosePro® (sumatriptan injection) - a needle-free delivery system for subcutaneous use, from Zogenix, Inc. for $85 million in cash and rights to additional cash payments based on the achievement of some commercial milestones. Additionally, Endo reported that it will assume an existing third party royalty obligation on net sales, and that the transaction will be financed with Endo's current cash on hand. The full analyst notes on Endo are available to download free of charge at:
http://www.analystsreview.com/2837-ENDP-23May2014.pdf
--
Baxter International Inc. Analyst Notes
On May 13, 2014, Baxter International Inc. (Baxter) reported that Stuart H. Altman, Ph.D. has been honored with the 2014 William B. Graham Prize for Health Services Research. According to the Company, the award recognizes the contributions of health services researchers who apply analytic methods to study and evaluate the organization, financing, and/or delivery of health services, in an effort to improve the health of the citizens by improving the delivery of health services. Baxter stated that the recipients of the award are being selected by an independent committee of past winners, distinguished academics, and internationally recognized researchers. The full analyst notes on Baxter are available to download free of charge at:
http://www.analystsreview.com/2837-BAX-23May2014.pdf
--
Edwards Lifesciences Corp Analyst Notes
On May 20, 2014, Edwards Lifesciences Corp (Edwards) announced that it has reached an agreement with Medtronic to settle all pending patent litigation between the two Companies including cases related to transcatheter heart valves. According to Edwards, the agreement that aims at dismissal of all pending cases of appeals in courts and patent offices worldwide, also include a provision for the Companies not to litigate patent disputes against each other in the field of transcatheter valves during the eight-year duration of the agreement. The Company added that under the terms of a patent cross-license agreement which is a part of the settlement, Medtronic will make a one-time payment to Edwards of $750 million, as well as quarterly license royalty payments until April 2022, based on a percentage of Medtronic CoreValve sales and subject to a minimum annual payment of $40 million. The full analyst notes on Edwards Lifesciences are available to download free of charge at:
http://www.analystsreview.com/2837-EW-23May2014.pdf
--
Aetna Inc Analyst Notes
On May 16, 2014, Aetna Inc (Aetna) reported that it is extending help to the members affected by wildfires in San Diego County by assisting them with obtaining refill prescriptions, as well as provide them access employee assistance, student assistance, and behavioral health programs. According to the Company, it has also extended claim and appeal filing time, and is helping members who have evacuated find care outside their home areas. Mark T. Bertolini, Chairman, CEO and President of Aetna said, "Our thoughts are with those affected by the wildfires burning in San Diego County. We are committed to helping our members get the care and medications they need, understanding that many may have evacuated from their homes and are unable to use their usual physicians, pharmacies and hospitals." The full analyst notes on Aetna are available to download free of charge at:
http://www.analystsreview.com/2837-AET-23May2014.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review